Evidence map›Paper›PMID 42386703›Full record

ArticleCell death & disease2026

FOXQ1 activates GLT8D2 to enhance CCL2 N-glycosylation and promote prostate cancer bone metastasis.

Zhiyue Xie, Nan Peng, Linglan Zhao, Chuqian Zhen, Xian-Lu Song, Yaying Hong, Qu Li, Tao Xie, Tianming Peng, Xianzi Zeng and 6 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zhiyue Xie *Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0009-0004-7851-2759
Nan Peng *Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0009-0004-2284-2265
Linglan Zhao *Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0009-0009-7106-358X
Chuqian Zhen *Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xian-Lu Song *Department of Radiotherapy, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China.
Yaying HongDepartment of Urology, Xiang'an Hospital, Xiamen University, Xiamen, China.
Qu LiDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Tao XieGuangdong Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Tianming PengDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, China.
Xianzi ZengDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, China.
Jinpeng CenDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, China.
Shengdong GeDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, China.
Xiaofeng LiuDepartment of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, China.
Ninghan FengDepartment of Urology, Jiangnan University Medical Center, Wuxi, China. n.feng@njmu.edu.cn.ORCID http://orcid.org/0000-0002-0892-6102
Mingkun ChenDepartment of Urology, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. mingkun07@163.com.ORCID http://orcid.org/0000-0003-2544-302X
Shan-Chao ZhaoDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China. lulululu@smu.edu.cn.ORCID http://orcid.org/0000-0002-1162-8077

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82272856National Natural Science Foundation of China (National Science Foundation of China) 82303742
6 · The paper itself

Abstract

Prostate cancer (PCa) is a common malignancy in men, and bone metastasis is a leading cause of mortality in advanced-stage PCa. This study aims to identify critical genes involved in PCa bone metastasis, exploring biomarkers for prognosis and precision treatment. Forkhead Box Q1 (FOXQ1) was identified as a potential key gene through screening of public databases, and was found to be markedly upregulated in bone metastatic PCa compared to primary PCa. FOXQ1 promotes PCa cell proliferation and metastasis while inhibiting apoptosis. Additionally, FOXQ1 recruits macrophages, promotes M2 polarization, and enhances osteoclast differentiation in the tumor microenvironment. Mechanistically, FOXQ1 activates the transcription of Glycosyltransferase 8 Domain Containing 2 (GLT8D2) by directly binding to its promoter, and GLT8D2 upregulates the expression of C-C Motif Chemokine Ligand 2 (CCL2) by enhancing its N-glycosylation, thereby promoting PCa bone metastasis. Collectively, these findings establish FOXQ1 as a key regulator of PCa bone metastasis through the GLT8D2/CCL2 axis, and suggest that targeting this pathway may hold therapeutic promise for bone metastatic PCa.

Indexed as

Bone NeoplasmsChemokine CCL2Forkhead Transcription FactorsGlycosyltransferasesProstatic NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGlycosylationHumansMaleMiceTumor MicroenvironmentCCL2 protein, humanChemokine CCL2Forkhead Transcription FactorsFOXQ1 protein, humanGlycosyltransferases

Identifiers

PMID42386703
PMCPMC13590482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.